Selected research
Industry Research
Biologics Regulatory Affairs Outsourcing Industry Research Report 2026
Market perspective
The global Biologics Regulatory Affairs Outsourcing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biologics Regulatory Affairs Outsourcing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biologics Regulatory Affairs Outsourcing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biologics Regulatory Affairs Outsourcing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biologics Regulatory Affairs Outsourcing include Lonza AG, Wuxi AppTec Inc., Thermo Fisher Scientific Inc., Eurofins Scientific SE, Freyr solutions, Catalent Inc., Piramal Group, AGC Biologics and ICON Plc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biologics Regulatory Affairs Outsourcing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biologics Regulatory Affairs Outsourcing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics Regulatory Affairs Outsourcing Market by Company
Lonza AG
Wuxi AppTec Inc.
Thermo Fisher Scientific Inc.
Eurofins Scientific SE
Freyr solutions
Catalent Inc.
Piramal Group
AGC Biologics
ICON Plc.
Charles River Laboratories International, Inc.
Labcorp
Parexel International
Medpace Holdings, Inc.
IQVIA
Syneos Health
SGS SA (SGS)
Biologics Regulatory Affairs Outsourcing Segment by Type
Regulatory Consulting
Legal Representation
Regulatory Writing & Publishing
Product Registration
Regulatory Submissions
Regulatory Operations
Others
Biologics Regulatory Affairs Outsourcing Segment by Application
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Cell & Gene Therapies
Biosimilars
Others
Biologics Regulatory Affairs Outsourcing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Regulatory Affairs Outsourcing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics Regulatory Affairs Outsourcing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Regulatory Affairs Outsourcing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biologics Regulatory Affairs Outsourcing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Regulatory Consulting
- Legal Representation
- Regulatory Writing & Publishing
- Product Registration
- Regulatory Submissions
- Regulatory Operations
- Others
Applications
- Monoclonal Antibodies (mAbs)
- Recombinant Proteins
- Vaccines
- Cell & Gene Therapies
- Biosimilars
- Others
Companies covered
- Lonza AG
- Wuxi AppTec Inc.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific SE
- Freyr solutions
- Catalent Inc.
- Piramal Group
- AGC Biologics
- ICON Plc.
- Charles River Laboratories International, Inc.
- Labcorp
- Parexel International
- Medpace Holdings, Inc.
- IQVIA
- Syneos Health
- SGS SA (SGS)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biologics Regulatory Affairs Outsourcing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Regulatory Consulting
- 2.2.3 Legal Representation
- 2.2.4 Regulatory Writing & Publishing
- 2.2.5 Product Registration
- 2.2.6 Regulatory Submissions
- 2.2.7 Regulatory Operations
- 2.2.8 Others
- 2.3 Biologics Regulatory Affairs Outsourcing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Monoclonal Antibodies (mAbs)
- 2.3.3 Recombinant Proteins
- 2.3.4 Vaccines
- 2.3.5 Cell & Gene Therapies
- 2.3.6 Biosimilars
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Biologics Regulatory Affairs Outsourcing Breakdown Data by Type
- 3.1 Global Biologics Regulatory Affairs Outsourcing Historic Market Size by Type (2021-2026)
- 3.2 Global Biologics Regulatory Affairs Outsourcing Forecasted Market Size by Type (2027-2032)
4 Biologics Regulatory Affairs Outsourcing Breakdown Data by Application
- 4.1 Global Biologics Regulatory Affairs Outsourcing Historic Market Size by Application (2021-2026)
- 4.2 Global Biologics Regulatory Affairs Outsourcing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biologics Regulatory Affairs Outsourcing Market Perspective (2021-2032)
- 5.2 Global Biologics Regulatory Affairs Outsourcing Growth Trends by Region
- 5.2.1 Global Biologics Regulatory Affairs Outsourcing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biologics Regulatory Affairs Outsourcing Historic Market Size by Region (2021-2026)
- 5.2.3 Biologics Regulatory Affairs Outsourcing Forecasted Market Size by Region (2027-2032)
- 5.3 Biologics Regulatory Affairs Outsourcing Market Dynamics
- 5.3.1 Biologics Regulatory Affairs Outsourcing Industry Trends
- 5.3.2 Biologics Regulatory Affairs Outsourcing Market Drivers
- 5.3.3 Biologics Regulatory Affairs Outsourcing Market Challenges
- 5.3.4 Biologics Regulatory Affairs Outsourcing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biologics Regulatory Affairs Outsourcing Players by Revenue
- 6.1.1 Global Top Biologics Regulatory Affairs Outsourcing Players by Revenue (2021-2026)
- 6.1.2 Global Biologics Regulatory Affairs Outsourcing Revenue Market Share by Players (2021-2026)
- 6.2 Global Biologics Regulatory Affairs Outsourcing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biologics Regulatory Affairs Outsourcing Head Office and Area Served
- 6.4 Global Biologics Regulatory Affairs Outsourcing Players, Product Type & Application
- 6.5 Global Biologics Regulatory Affairs Outsourcing Manufacturers Established Date
- 6.6 Global Biologics Regulatory Affairs Outsourcing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biologics Regulatory Affairs Outsourcing Market Size (2021-2032)
- 7.2 North America Biologics Regulatory Affairs Outsourcing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biologics Regulatory Affairs Outsourcing Market Size by Country (2021-2026)
- 7.4 North America Biologics Regulatory Affairs Outsourcing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biologics Regulatory Affairs Outsourcing Market Size (2021-2032)
- 8.2 Europe Biologics Regulatory Affairs Outsourcing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biologics Regulatory Affairs Outsourcing Market Size by Country (2021-2026)
- 8.4 Europe Biologics Regulatory Affairs Outsourcing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biologics Regulatory Affairs Outsourcing Market Size (2021-2032)
- 9.2 Asia-Pacific Biologics Regulatory Affairs Outsourcing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biologics Regulatory Affairs Outsourcing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biologics Regulatory Affairs Outsourcing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biologics Regulatory Affairs Outsourcing Market Size (2021-2032)
- 10.2 South America Biologics Regulatory Affairs Outsourcing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biologics Regulatory Affairs Outsourcing Market Size by Country (2021-2026)
- 10.4 South America Biologics Regulatory Affairs Outsourcing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biologics Regulatory Affairs Outsourcing Market Size (2021-2032)
- 11.2 Middle East & Africa Biologics Regulatory Affairs Outsourcing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biologics Regulatory Affairs Outsourcing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biologics Regulatory Affairs Outsourcing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza AG
- 12.1.1 Lonza AG Company Information
- 12.1.2 Lonza AG Business Overview
- 12.1.3 Lonza AG Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.1.4 Lonza AG Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.1.5 Lonza AG Recent Developments
- 12.2 Wuxi AppTec Inc.
- 12.2.1 Wuxi AppTec Inc. Company Information
- 12.2.2 Wuxi AppTec Inc. Business Overview
- 12.2.3 Wuxi AppTec Inc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.2.4 Wuxi AppTec Inc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.2.5 Wuxi AppTec Inc. Recent Developments
- 12.3 Thermo Fisher Scientific Inc.
- 12.3.1 Thermo Fisher Scientific Inc. Company Information
- 12.3.2 Thermo Fisher Scientific Inc. Business Overview
- 12.3.3 Thermo Fisher Scientific Inc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.3.4 Thermo Fisher Scientific Inc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.3.5 Thermo Fisher Scientific Inc. Recent Developments
- 12.4 Eurofins Scientific SE
- 12.4.1 Eurofins Scientific SE Company Information
- 12.4.2 Eurofins Scientific SE Business Overview
- 12.4.3 Eurofins Scientific SE Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.4.4 Eurofins Scientific SE Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.4.5 Eurofins Scientific SE Recent Developments
- 12.5 Freyr solutions
- 12.5.1 Freyr solutions Company Information
- 12.5.2 Freyr solutions Business Overview
- 12.5.3 Freyr solutions Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.5.4 Freyr solutions Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.5.5 Freyr solutions Recent Developments
- 12.6 Catalent Inc.
- 12.6.1 Catalent Inc. Company Information
- 12.6.2 Catalent Inc. Business Overview
- 12.6.3 Catalent Inc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.6.4 Catalent Inc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.6.5 Catalent Inc. Recent Developments
- 12.7 Piramal Group
- 12.7.1 Piramal Group Company Information
- 12.7.2 Piramal Group Business Overview
- 12.7.3 Piramal Group Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.7.4 Piramal Group Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.7.5 Piramal Group Recent Developments
- 12.8 AGC Biologics
- 12.8.1 AGC Biologics Company Information
- 12.8.2 AGC Biologics Business Overview
- 12.8.3 AGC Biologics Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.8.4 AGC Biologics Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.8.5 AGC Biologics Recent Developments
- 12.9 ICON Plc.
- 12.9.1 ICON Plc. Company Information
- 12.9.2 ICON Plc. Business Overview
- 12.9.3 ICON Plc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.9.4 ICON Plc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.9.5 ICON Plc. Recent Developments
- 12.10 Charles River Laboratories International, Inc.
- 12.10.1 Charles River Laboratories International, Inc. Company Information
- 12.10.2 Charles River Laboratories International, Inc. Business Overview
- 12.10.3 Charles River Laboratories International, Inc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.10.4 Charles River Laboratories International, Inc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.10.5 Charles River Laboratories International, Inc. Recent Developments
- 12.11 Labcorp
- 12.11.1 Labcorp Company Information
- 12.11.2 Labcorp Business Overview
- 12.11.3 Labcorp Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.11.4 Labcorp Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.11.5 Labcorp Recent Developments
- 12.12 Parexel International
- 12.12.1 Parexel International Company Information
- 12.12.2 Parexel International Business Overview
- 12.12.3 Parexel International Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.12.4 Parexel International Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.12.5 Parexel International Recent Developments
- 12.13 Medpace Holdings, Inc.
- 12.13.1 Medpace Holdings, Inc. Company Information
- 12.13.2 Medpace Holdings, Inc. Business Overview
- 12.13.3 Medpace Holdings, Inc. Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.13.4 Medpace Holdings, Inc. Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.13.5 Medpace Holdings, Inc. Recent Developments
- 12.14 IQVIA
- 12.14.1 IQVIA Company Information
- 12.14.2 IQVIA Business Overview
- 12.14.3 IQVIA Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.14.4 IQVIA Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.14.5 IQVIA Recent Developments
- 12.15 Syneos Health
- 12.15.1 Syneos Health Company Information
- 12.15.2 Syneos Health Business Overview
- 12.15.3 Syneos Health Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.15.4 Syneos Health Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.15.5 Syneos Health Recent Developments
- 12.16 SGS SA (SGS)
- 12.16.1 SGS SA (SGS) Company Information
- 12.16.2 SGS SA (SGS) Business Overview
- 12.16.3 SGS SA (SGS) Revenue in Biologics Regulatory Affairs Outsourcing Business (2021-2026)
- 12.16.4 SGS SA (SGS) Biologics Regulatory Affairs Outsourcing Product Portfolio
- 12.16.5 SGS SA (SGS) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst